Inducible Animal-Cell VLP Expression for Scalable Vaccine Antigens
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing vaccine technologies face challenges in rapidly producing stable and large-scale virus-like particles (VLPs) for emerging infectious diseases like COVID-19 and influenza, with conventional methods being risky and inefficient, and there is a need for improved systems that can co-express multiple genes to enhance immunogenicity and stability.
Innovation Solution
An animal cell expression system using inducible expression cassettes and site-specific recombinase technology to stably express VLPs, such as those for SARS-CoV-2 and influenza, allowing for rapid, large-scale production and efficient self-assembly of VLPs, including spike and envelope proteins, with the use of adjuvants to enhance immune responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If conventional virus-based vaccines are used, then immunogenicity is improved, but safety risks increase due to large-scale virus cultures and incomplete inactivation
Solution Approach 1:
The patent creates virus-like particles (VLPs) that copy the structural features and immunogenic properties of actual viruses without containing functional viral genomes. The VLPs are composed of viral structural proteins (capsid, envelope, spike proteins) that self-assemble to mimic native virus morphology and antigenicity, providing immune stimulation without the safety risks of live or inactivated whole viruses
Solution Approach 2:
The patent extracts only the essential immunogenic components (structural proteins) from the complete virus, discarding the harmful viral genome and replication machinery. By expressing and assembling only the capsid, envelope, and spike proteins in eukaryotic cells, the system produces particles that retain antigenic properties while eliminating pathogenicity
2Reliability
If protein-based vaccines are used, then safety is improved, but immunogenicity decreases requiring adjuvants
Solution Approach 1:
The patent creates composite viral-like structures by co-expressing multiple protein components (capsid protein, envelope protein, and spike protein) that self-assemble into complex particulate structures. This composite organization of proteins mimics the natural virus architecture, providing enhanced immunogenicity through particulate features that facilitate antigen presentation while maintaining the safety of recombinant protein expression
Solution Approach 2:
The patent implements hierarchical protein assembly where smaller structural units (capsid proteins) form intermediate structures that are further organized by envelope and spike proteins into complete virus-like particles. This nested self-assembly process creates progressively more complex immunogenic structures from individual protein subunits
3Loss of time
If rapid response to emerging diseases is needed, then vaccine development speed is improved, but manufacturing stability decreases
Solution Approach 1:
The patent establishes a universal eukaryotic expression platform that can produce VLPs for different viruses (coronaviruses, influenza, HIV, hepatitis) using the same system architecture. The platform accepts different viral structural protein genes and produces appropriate VLPs through identical expression and self-assembly mechanisms, enabling rapid adaptation to emerging diseases while maintaining manufacturing consistency
Solution Approach 2:
The patent pre-establishes stable eukaryotic cell lines with inducible expression systems and optimized protein assembly conditions before outbreaks occur. The system is prepared with validated expression cassettes, cell banks, and purification protocols that can be rapidly activated to produce VLPs for new viral targets through simple gene sequence substitution
4Ease of manufacture
If multiple genes are co-expressed for VLP production, then immunogenicity is improved, but device complexity increases
Solution Approach 1:
The patent combines multiple viral structural protein expression cassettes into a single integrated expression system within eukaryotic cells. The co-expression of capsid, envelope, and spike proteins from multiple genes is coordinated through shared regulatory elements and cellular machinery, simplifying the overall manufacturing process while producing the complete set of proteins needed for authentic VLP assembly
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The system enables high-yield production of VLPs that induce robust immune responses, effectively preventing viral infections and replication, and can adapt to emerging variants like Delta and Omicron, providing rapid vaccine development capabilities.
Implementation Method 1
inducible expression cassette for one or more site-specific recombinant VLP genes
Data Source
AI summary
The disclosure provides an animal cell stably expressing a virus-like particle (VLP). The disclosure also provides a method for manufacturing a virus-like particle, a virus-like particle, a vaccine composition, a method for preventing viral infection, and a method for producing antibodies.